Literature DB >> 29022745

Real world adherence to oral anticoagulant in non-valvular atrial fibrillation patients in China.

Xiao Xiang1, Yaying Cao1, Kexin Sun1, Jing Song1, Yaohua Tian1, Qiongzhou Yin1, Juan Juan1, Yonghua Hu1.   

Abstract

BACKGROUND AND
OBJECTIVE: Adherence to oral anticoagulants is crucial for the prevention of ischemic stroke in atrial fibrillation patients; however, evidence of oral-anticoagulant adherence from developing countries is still lacking. This study aimed to evaluate the current situation and predictors of oral-anticoagulant adherence in non-valvular atrial fibrillation (NVAF) patients in China.
METHODS: Records of NVAF patients were obtained from a regional claims database. Both initiation and adherence to oral anticoagulants were calculated from linked records. Factors of oral-anticoagulant initiation were identified using Cox regression.
RESULTS: Among 33,463 NVAF patients, only 13.9% initialized warfarin treatment after the indexed hospital visit. Stratified by CHA2DS2-VASc scores, 20.9% of patients in the low-risk group were on warfarin, followed by 15.3% and 10.7% from the middle and high-risk groups, respectively. Among patients who initialized warfarin, only 40.4% filled the first repeat prescription within 3 months. Concurrent statin use, hypertension and heart failure were associated with higher warfarin initiation rate. Factors such as age above 75, female sex, manufacture workers, discharge from the primary-care center, antiplatelet use, and diabetes, ischemic and hemorrhagic stroke were associated with lower rate of warfarin initiation. Additionally, initiating warfarin treatment reduced risk of ischemic stroke in middle and high-risk patients.
CONCLUSION: Oral anticoagulation was significantly under-used in NVAF patients in China. Age, sex, concurrent drug usage, and disease history were associated factors. Improving warfarin adherence was promising to reduce ischemic stroke risk of NVAF patients.

Entities:  

Keywords:  Atrial fibrillation; adherence; ischemic stroke; oral anticoagulant; risk factors

Mesh:

Substances:

Year:  2017        PMID: 29022745     DOI: 10.1080/03007995.2017.1391760

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  5 in total

1.  Sex Differences in Efficacy and Safety After Left Atrial Appendage Closure: A 4.3-Year Follow-Up Analysis.

Authors:  Yuyi Chen; Yonghua Zhang; Lulu Qu; Chunyu Chen; Xi Su; Yanhong Chen
Journal:  Front Cardiovasc Med       Date:  2022-05-18

2.  Risk factors for calciphylaxis in Chinese hemodialysis patients: a matched case-control study.

Authors:  Yuqiu Liu; Xiaoliang Zhang; Xiaotong Xie; Xin Yang; Hong Liu; Rining Tang; Bicheng Liu
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

3.  Adherence to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study.

Authors:  Ayman J Hammoudeh; Yousef Khader; Nazih Kadri; Eyas Al-Mousa; Yahya Badaineh; Laith Habahbeh; Ramzi Tabbalat; Hesham Janabi; Imad A Alhaddad
Journal:  Int J Vasc Med       Date:  2021-04-08

4.  Medication adherence for atrial fibrillation patients: triangulating measures from a smart pill bottle, e-prescribing software, and patient communication through the electronic health record.

Authors:  Tammy Toscos; Michelle Drouin; Jessica A Pater; Mindy Flanagan; Shauna Wagner; Amanda Coupe; Ryan Ahmed; Michael J Mirro
Journal:  JAMIA Open       Date:  2020-04-28

5.  The microvesicle/CD36 complex triggers a prothrombotic phenotype in patients with non-valvular atrial fibrillation.

Authors:  Hua Wang; Nian-Peng Song; Jian-Ping Li; Zhi-Hao Wang; Yun Ti; Yi-Hui Li; Wei Zhang; Ming Zhong
Journal:  J Cell Mol Med       Date:  2020-06-08       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.